" class="no-js "lang="en-US"> Brad O'Connor - Medtech Alert
Sunday, September 21, 2025

Breaking News

Eloxx Pharmaceuticals Announces Final Data Assessment from Phase 2 Combination Clinical Trial of ELX-02 in Class 1 Cystic Fibrosis Patients Verge Genomics Announces Positive Safety and Tolerability Data from the Phase 1 Clinical Trial of VRG50635, a Potential Best-in-Class Therapeutic for All Forms of ALS DEM BioPharma Appoints Wendy Young, Ph.D., to Scientific Advisory Board Confo Therapeutics Enters into Research Collaboration for GPCR-Targeting Antibody Discovery with AbCellera Vyriad Announces Expansion of T-Cell Lymphoma Trial at Mayo Clinic Astellas and Cullgen Enter into Strategic Collaboration and Option Agreement to Advance Innovative Targeted Protein Degraders Auxilius Pharma Raises Seed Funding of $1 Million and Commences its Clinical Program Captivate Bio and EverCell Bio partner on Human Cell Modeling Services for Cell and Gene Therapy Markets Applied StemCell Partners with CIRM to Provide Clinical-Grade iPSCs and Access to Its Proprietary Gene Editing Technologies Alentis Therapeutics Receives IND Clearance from FDA for ALE.C04 for the Treatment of CLDN1+ Tumors
Brad O'Connor

Brad O’Connor

About Brad O’Connor

Brad O’Connor has been Managing Director and Chief Executive Officer of Cogstate Limited since December 2005. He has responsibility for Cogstate’s overall strategic direction and day-to-day operations as well as development of expansion opportunities outside of the core clinical trials business.

Related Story

Clinical Trials

 Clario and Cogstate Expand Partnership to Deliver Leading Data Collection and Data Quality Programs for Neuroscience Clinical Trials | Pharmtech Focus

Clario and Cogstate Expand Partnership to Deliver Leading Data Collection and Data Quality Programs for Neuroscience Clinical Trials

May 23 2022

Clario, a technology company that delivers the leading endpoint solutions for decentralized (DCT), hybrid and […]